{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:05:03Z","timestamp":1789643103371,"version":"4.0.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273529"],"award-info":[{"award-number":["82273529"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jaad.2026.06.064","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:26:11Z","timestamp":1783617971000},"page":"1028-1034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world outcomes of 24-week abrocitinib tapering in moderate-to-severe atopic dermatitis: Feasibility and regimen comparison"],"prefix":"10.1016","volume":"95","author":[{"given":"Sisi","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanxiong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiquan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jaad.2026.06.064_bib1","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/bjd.19580","article-title":"The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990-2017","volume":"184","author":"Laughter","year":"2021","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2026.06.064_bib2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jaad.2022.04.009","article-title":"Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND)","volume":"87","author":"Shi","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2026.06.064_bib3","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1111\/jdv.19378","article-title":"Real-world effectiveness of abrocitinib treatment in patients with difficult-to-treat atopic dermatitis","volume":"37","author":"Olydam","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2026.06.064_bib4","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/all.15952","article-title":"Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis and comorbid allergies","volume":"79","author":"Schmid-Grendelmeier","year":"2024","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.jaad.2026.06.064_bib5","first-page":"702","article-title":"Atopic dermatitis relapse after treatment discontinuation and predictive factors for relapse: JAK1 inhibitors versus dupilumab","volume":"23","author":"Wu","year":"2025","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"10.1016\/j.jaad.2026.06.064_bib6","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1089\/derm.2024.0014","article-title":"Efficacy, safety, and early relapse after cessation of upadacitinib versus dupilumab in adolescents with moderate-to-severe atopic dermatitis: a real-world study in China","volume":"35","author":"Zhu","year":"2024","journal-title":"Dermatitis"},{"issue":"1","key":"10.1016\/j.jaad.2026.06.064_bib7","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","article-title":"Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial","volume":"86","author":"Blauvelt","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2026.06.064_bib8","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s40257-025-00923-1","article-title":"Upadacitinib dose reduction regimen in elderly patients with atopic dermatitis, guided by treat-to-target consensus recommendations","volume":"26","author":"Tong","year":"2025","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2026.06.064_bib9","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v105.44165","article-title":"Successful dose reduction of janus-kinase inhibitors in well-controlled atopic dermatitis: a prospective, multicentre, real-world study","volume":"105","author":"Schl\u00f6sser","year":"2025","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2026.06.064_bib10","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/bjd\/ljad011","article-title":"Successful dose reduction of dupilumab in atopic dermatitis","volume":"188","author":"Ardern-Jones","year":"2023","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2026.06.064_bib11","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.jaad.2025.12.020","article-title":"Sustaining treatment response in alopecia areata through tofacitinib dose tapering: a single-center retrospective study","volume":"94","author":"Huang","year":"2026","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2026.06.064_bib12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000545704","article-title":"Investigation of the clinical remission course in ulcerative colitis from tofacitinib induction to tapering or withdrawal in Japanese patients: a single-center retrospective study","volume":"10","author":"Koroku","year":"2025","journal-title":"Inflamm Intest Dis"},{"issue":"2","key":"10.1016\/j.jaad.2026.06.064_bib13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/annrheumdis-2018-213271","article-title":"Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.jaad.2026.06.064_bib14","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1111\/all.15439","article-title":"Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis","volume":"77","author":"Spekhorst","year":"2022","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.jaad.2026.06.064_bib15","doi-asserted-by":"crossref","first-page":"e691","DOI":"10.1111\/jdv.18908","article-title":"Dose reduction of dupilumab in atopic patients with controlled atopic dermatitis: a safe and effective practice?","volume":"37","author":"Mastorino","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"10.1016\/j.jaad.2026.06.064_bib16","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1124\/dmd.122.000829","article-title":"The pharmacokinetics, metabolism, and clearance mechanisms of abrocitinib, a selective Janus kinase inhibitor, in humans","volume":"50","author":"Bauman","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jaad.2026.06.064_bib17","series-title":"Cibinqo: Summary of Product Characteristics","first-page":"21","year":"2021"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222602952X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222602952X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:58:52Z","timestamp":1789642732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096222602952X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S019096222602952X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2026.06.064","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world outcomes of 24-week abrocitinib tapering in moderate-to-severe atopic dermatitis: Feasibility and regimen comparison","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2026.06.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}